Evidence map›Paper›PMID 36016800›Full record

ArticleFrontiers in microbiology2022

Corrigendum: Development of phage cocktails to treat

Belkys C Sanchez, Emmaline R Heckmann, Sabrina I Green, Justin R Clark, Heidi B Kaplan, Robert F Ramig, Kenneth L Muldrew, Casey Hines-Munson, Felicia Skelton, Barbara W Trautner and 1 more

Abstract readPublished Erratum
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Phage Therapy-Challenges, Opportunities and Future Prospects.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Belkys C SanchezTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States.
Emmaline R HeckmannTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States.
Sabrina I GreenTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States.
Justin R ClarkTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States.
Heidi B KaplanDepartment of Microbiology and Molecular Genetics, McGovern Medical School, UTHealth Houston, Houston, TX, United States.
Robert F RamigTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States.
Kenneth L MuldrewDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.
Casey Hines-MunsonCenter for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, TX, United States.
Felicia SkeltonCenter for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, TX, United States.
Barbara W TrautnerCenter for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, TX, United States.
Anthony W MaressoTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States.

Funding

Bacteriophage to treat multidrug‐resistant UTI in Persons with Spinal Cord InjuryI01RX002595 · VA · MICHAEL E DEBAKEY VA MEDICAL CENTER · PI TRAUTNER, BARBARA WELLS · 2019 to 2023
–
Optimizing Bacteriuria Management in Veterans with Spinal Cord InjuryIK2HX002484 · VA · MICHAEL E DEBAKEY VA MEDICAL CENTER · PI SKELTON, FELICIA · 2018 to 2022
–
HSRD VA IK2 HX002484RRD VA I01 RX002595
6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fmicb.2022.796132.].

Indexed as

biofilmsCAUTImultidrug-resistancephage therapyuropathogenic E. coli

Identifiers

PMID36016800
PMCPMC9396641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.